Viewing nowDong-A Dapagliflozin 10 mg (Dapagliflozin Propanediol Hydrate)
Dapagliflozin Propanediol Hydrate
Tablet · Prescription medication
Dong-A ST Co., Ltd.

MFDS item code 202300340 · Approved 2023.01.26 · Insurance code 642507730
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with type 2 diabetes. It is administered as an adjunct to diet and exercise, and can be used alone or in combination with other medications. Caution is needed for patients with cardiovascular disease or risk factors among those who have difficulty controlling blood sugar levels. This medication improves blood sugar levels and aids in diabetes management.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior experience of pharmacological treatment for diabetes, when this medicine is administered in combination with metformin, the recommended initial dose is 5mg once daily or 10mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Older adults (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of day, with or without food. The tablets should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This medication should not be used by individuals who have had allergic reactions to the active ingredient or excipients. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Contains lactose hydrate; individuals with lactose intolerance or related genetic disorders should not take this medication. It is not recommended for patients undergoing dialysis. Patients with fluid volume deficits or diminished kidney function should have their condition thoroughly evaluated prior to use, and blood pressure and kidney function should be monitored periodically after administration. In patients with moderate to severe renal impairment, caution is necessary as the blood sugar control effect may be reduced. The most commonly reported side effect in clinical trials is genital infections, which may occur more frequently in women and in those with a history of past infections. Hypoglycemia may occur primarily when this medication is used in conjunction with insulin or sulfonylureas, so dosage adjustments may be necessary when used together with these medications. This medication may cause symptoms of fluid volume depletion such as dehydration, hypotension, and thirst; therefore, fluid status should be monitored closely. Diabetic ketoacidosis may rarely occur, so immediate medical attention is necessary upon symptom onset. The risk of urinary infections, such as urinary tract infections and pyelonephritis, may increase, so prompt treatment is required if infection symptoms appear. This medication may affect kidney function, so it is important to regularly check kidney function test results. Severe infections, such as perineal necrosis, have been reported rarely; immediately consult a physician if there is pain or swelling in the perineum. The use of this medication is not recommended during pregnancy, and it should be discontinued upon confirmation of pregnancy. It is also safest not to use this medication while breastfeeding. In children, the safety and efficacy of this medication have not been established, and it is not used in this population. There is no specific antidote in the event of overdose, so symptomatic treatment will be provided according to the symptoms. This medication does not significantly affect driving or machine operation, but caution is advised if there is a risk of hypoglycemia. Keep this medication out of reach of children and store it in its original container.
Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal gangrene, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, increased hematocrit, decreased renal creatinine clearance at the beginning of treatment, dyslipidemia, elevated serum creatinine at the beginning of treatment, elevated blood urea, weight loss, acute pyelonephritis, rash, angioedema, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina, myocardial infarction, cholangitis, biliary stones, alcoholic liver cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, sensory abnormalities, cerebral infarction, nerve compression, sensory loss, headache, nasopharyngitis, upper respiratory infection, edema, fever, foreign body sensation, facial edema, facial pain, warmth, flu-like symptoms, chest pain, fatigue, chest discomfort, peripheral edema, generalized edema, hunger, breast lump, erectile dysfunction, benign prostatic hyperplasia, breast pain, genital rash, menorrhagia, genital edema, uterine bleeding, vaginal bleeding, vulvar discomfort, menstrual irregularities, itching, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, shortness of breath, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture intrusion. It is recommended to maintain storage temperatures between 1 to 30 degrees Celsius.
Yellow round film-coated tablets
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowDapagliflozin Propanediol Hydrate
Tablet · Prescription medication
Dong-A ST Co., Ltd.
Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Sung IS Co., Ltd.
Dapagliflozin Propanediol Hydrate
Prescription medication
Optus Pharmaceutical Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Aprogen Biologics Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.